April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now